Welcome to our dedicated page for USANA HEALTH SCIENCES SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
USANA Health Sciences reported Q3 2025 net sales of $213.7 million, up 6.7% year over year, driven by the addition of the Hiya direct‑to‑consumer business ($30.8 million) and growth in “Other,” which offset declines in direct selling.
The quarter showed a net loss of $6.5 million versus earnings of $10.6 million a year ago. Management cites a sharp increase in the annualized effective tax rate to 65% and higher selling, general and administrative costs, including amortization of acquired intangibles and elevated marketing at Hiya. Gross margin was 77.2% (down 320 bps), reflecting Hiya’s lower gross margin mix and higher “Other.”
Direct selling net sales fell as active customers decreased to 388,000, with broad softness across Asia Pacific and Americas/Europe. Cash and cash equivalents were $145.3 million and there was no balance on the $75 million revolver at quarter‑end. Year to date, USANA repurchased 927,000 shares for $27.7 million, leaving $34.0 million authorized. As of October 31, 2025, shares outstanding were 18,280,857. Subsequently, the company initiated a cost alignment program with an expected $4.7 million one‑time Q4 charge.
USANA Health Sciences (USNA) director reported a sale of 1,057 shares of common stock (Code S) at $21.4799 on 11/03/2025. Following the transaction, the director beneficially owned 0 shares, held as direct ownership (D).
USANA Health Sciences (USNA) reported an insider transaction on a Form 4. A company director sold 1,750 shares of Common Stock on 10/31/2025 at a price of $19.79 per share (transaction code: S for open-market sale). After this trade, the insider directly beneficially owns 4,565 shares.
USANA Health Sciences (USNA) — director Form 4 activity. On 10/23/2025, 1,057 shares of common stock were acquired via the vesting/settlement of restricted stock units (code M). To cover taxes, 606 shares were withheld/disposed at $20.63 (code F). Following these transactions, the director directly owned 4,586 shares. The related RSU award had a $0 exercise price and continues to vest in scheduled 25% installments on specified dates.
USANA Health Sciences (USNA) reported an insider transaction by a director on 10/23/2025. The filing shows the conversion of restricted stock units into 1,057 shares of common stock (Transaction Code M) and a separate Code F disposition of 265 shares at $20.63 per share.
Following these transactions, the reporting person directly held 9,027 shares of common stock and 2,115 restricted stock units. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) reported an insider stock acquisition by a director. On 10/23/2025, the director acquired 1,057 shares of common stock through the settlement of restricted stock units, coded M (derivative conversion).
The shares were delivered at a stated price of $0. Following the transaction, the director beneficially owns 7,986 shares directly, with 2,115 RSUs remaining outstanding. Each RSU represents the right to receive one share of USNA common stock. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) disclosed a Form 4 showing a director acquired 1,057 shares of common stock on 10/23/2025 via transaction code M, reflecting the settlement of restricted stock units into shares.
Following the transaction, the director beneficially owned 7,698 common shares directly. The filing also shows 2,115 restricted stock units beneficially owned after the event, with vesting scheduled at 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. The derivative security price is listed as $0, consistent with RSU settlement.
USANA Health Sciences (USNA) reported a director’s acquisition of 1,057 shares of common stock on 10/23/2025, coded “M” for settlement of restricted stock units.
After the transaction, the reporting person beneficially owns 1,057 shares directly and 2,115 restricted stock units. The RSUs vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) disclosed an insider transaction by a director on 10/23/2025. The filing reports the acquisition of 1,057 shares of common stock via the settlement of restricted stock units (Transaction Code M). Following the transaction, the reporting person directly owns 6,315 common shares and holds 2,115 restricted stock units.
The RSUs vest in four equal installments of 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. The RSU settlement carried a stated price of $0 for the underlying common shares, consistent with equity award vesting mechanics.
USANA Health Sciences (USNA) disclosed insider activity dated 10/23/2025. A director acquired 1,057 shares of common stock through the conversion of restricted stock units (code M) and disposed of 476 shares (code F) at $20.63.
After the transactions, the director beneficially owned 5,918 common shares directly and held 2,115 restricted stock units. These RSUs vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.